サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1533656

セファロスポリン系薬剤の世界市場

Cephalosporin Drugs

出版日
ページ情報
英文 398 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
セファロスポリン系薬剤の世界市場
出版日: 2024年08月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 398 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

セファロスポリン系薬剤の世界市場は2030年までに223億米ドルに達する見込み

2023年に188億米ドルと推定されるセファロスポリン系薬剤の世界市場は、2023年から2030年にかけてCAGR 2.4%で成長し、2030年には223億米ドルに達すると予測されます。本レポートで分析しているセグメントの1つである第一世代セファロスポリン系薬剤は、CAGR 1.6%を記録し、分析期間終了時には45億米ドルに達すると予測されます。第二世代セファロスポリン系薬剤セグメントの成長率は、分析期間中CAGR 2.3％と推定されます。

米国市場は51億米ドル、中国はCAGR 4.2％で成長予測

米国のセファロスポリン系薬剤市場は2023年に51億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに42億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.1%と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界のセファロスポリン系薬剤市場- 主要動向と促進要因のまとめ

セファロスポリン系薬剤は、以前はセファロスポリウム（Cephalosporium）として知られていたアクレモニウム（Acremonium）菌に由来するβラクタム系抗生物質の大きなグループです。これらの抗生物質は5つの世代に分類され、それぞれがより広範囲の細菌を標的とし、耐性菌の発生に対抗するように設計されています。セファレキシンのような第一世代のセファロスポリンは、主にグラム陽性菌と一部のグラム陰性菌に有効です。後世代になるにつれて、これらの抗生物質はグラム陰性菌に対してより高い活性を示すようになり、β-ラクタマーゼ（多くのβ-ラクタム系抗生物質を不活性化できる細菌が産生する酵素）に対する耐性も強くなります。例えば、セフトリアキソンやセフォタキシムのような第3世代セファロスポリンは、それ以前の世代に耐性を持つ細菌も含め、幅広い細菌感染症に高い効果を示します。セフタロリンのような第5世代セファロスポリンは、メチシリン耐性黄色ブドウ球菌（MRSA）やその他の多剤耐性病原体をターゲットとして開発され、抗菌薬療法の大きな進歩を示しています。

セファロスポリン系薬剤の開発と使用は、細菌感染症の治療に革命をもたらし、感染症との闘いに不可欠な手段を提供しました。これらの薬剤は、肺炎、尿路感染症、皮膚感染症、敗血症などの治療に臨床現場で広く使用されています。広域スペクトル活性、比較的低い毒性、ペニシリン系と比較して少ないアレルギー反応により、抗生物質治療の要となっています。さらに、セファロスポリン系抗菌薬は、術後感染を予防するために外科手術の現場で予防的に使用されることが多く、現代医学におけるその重要な役割がさらに強調されています。しかしながら、耐性菌の継続的な進化は重大な課題となっており、耐性株と効果的に闘い、この重要な薬剤の継続的な有効性を確保できる新しいセファロスポリンを創出するための継続的な研究開発が必要とされています。

セファロスポリン系薬剤市場の成長は、細菌感染症の有病率の上昇や、効果的で広範囲な抗生物質に対する需要の増加など、いくつかの要因によってもたらされます。医薬品開発における技術の進歩や、これらの抗生物質の薬物動態学的・薬力学的プロファイルを改善するための継続的な努力が、市場拡大に大きく寄与しています。細菌感染に対して迅速かつ効果的な治療を求める消費者の行動は、抗生物質耐性の世界の脅威と相まって、新しいセファロスポリンの開発への投資に拍車をかけています。さらに、耐性菌に対処するための新規抗生物質の開発に対する規制当局の支援と後押しが、承認と商業化のプロセスを加速させています。ヘルスケアのインフラが拡大し、新興市場で抗生物質が入手しやすくなっていることも、市場の成長をさらに後押ししています。これらの要因が相まって、セファロスポリン系薬剤市場の持続的な成長と革新が保証され、感染症管理における現在および将来の課題に対処する抗生物質の重要性が浮き彫りになっています。

調査対象企業の例（全56件）

  • AbbVie, Inc.
  • Alkem Laboratories Limited
  • AristoPharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • China Union Chempharma（Suzhou）Co., Ltd.
  • Covalent Laboratories Pvt Ltd.
  • CSPC Pharmaceutical Group Co., Ltd.
  • Dhanuka Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Fujian Fukang Pharmaceutical Co., Ltd.
  • Hetero Healthcare Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP27106

Global Cephalosporin Drugs Market to Reach US$22.3 Billion by 2030

The global market for Cephalosporin Drugs estimated at US$18.8 Billion in the year 2023, is expected to reach US$22.3 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. First Generation Cephalosporin Drugs, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$4.5 Billion by the end of the analysis period. Growth in the Second Generation Cephalosporin Drugs segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 4.2% CAGR

The Cephalosporin Drugs market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Cephalosporin Drugs Market - Key Trends and Drivers Summarized

Cephalosporin drugs are a large group of beta-lactam antibiotics originally derived from the fungus Acremonium, which was previously known as Cephalosporium. These antibiotics are classified into five generations, each designed to target a broader range of bacteria and to counteract the development of bacterial resistance. First-generation cephalosporins, such as cephalexin, are primarily effective against gram-positive bacteria and some gram-negative bacteria. As we move to later generations, these antibiotics exhibit enhanced activity against gram-negative bacteria and greater resistance to beta-lactamases, enzymes produced by bacteria that can deactivate many beta-lactam antibiotics. For instance, third-generation cephalosporins like ceftriaxone and cefotaxime are highly effective against a wide array of bacterial infections, including those resistant to earlier generations. Fifth-generation cephalosporins, such as ceftaroline, have been developed to target methicillin-resistant Staphylococcus aureus (MRSA) and other multidrug-resistant pathogens, marking a significant advancement in antimicrobial therapy.

The development and use of cephalosporin drugs have revolutionized the treatment of bacterial infections, providing essential tools in the fight against infectious diseases. These drugs are widely used in clinical settings for the treatment of conditions such as pneumonia, urinary tract infections, skin infections, and septicemia. Their broad-spectrum activity, relatively low toxicity, and fewer allergic reactions compared to penicillins have made them a cornerstone in antibiotic therapy. Additionally, cephalosporins are often used prophylactically in surgical settings to prevent postoperative infections, further underscoring their critical role in modern medicine. The continued evolution of bacterial resistance, however, has posed significant challenges, necessitating ongoing research and development to create new cephalosporins that can effectively combat resistant strains and ensure the continued efficacy of these vital drugs.

The growth in the cephalosporin drugs market is driven by several factors, including the rising prevalence of bacterial infections and the increasing demand for effective and broad-spectrum antibiotics. Technological advancements in drug development and the continuous effort to improve the pharmacokinetic and pharmacodynamic profiles of these antibiotics have significantly contributed to market expansion. Consumer behavior towards seeking prompt and effective treatment for bacterial infections, coupled with the global threat of antibiotic resistance, has spurred investment in the development of new cephalosporins. Additionally, regulatory support and the push for the development of novel antibiotics to address resistant strains have accelerated the approval and commercialization processes. The expansion of healthcare infrastructure and the increasing accessibility of antibiotics in emerging markets further drive market growth. These factors collectively ensure the sustained growth and innovation within the cephalosporin drugs market, highlighting the importance of these antibiotics in addressing current and future challenges in infectious disease management.

Select Competitors (Total 56 Featured) -

  • AbbVie, Inc.
  • Alkem Laboratories Limited
  • AristoPharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • China Union Chempharma (Suzhou) Co., Ltd.
  • Covalent Laboratories Pvt Ltd.
  • CSPC Pharmaceutical Group Co., Ltd.
  • Dhanuka Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Fujian Fukang Pharmaceutical Co., Ltd.
  • Hetero Healthcare Ltd.
  • Macleods Pharmaceuticals Ltd.
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Cephalosporin Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Antibiotic Resistance and Its Implications for Cephalosporin Efficacy
    • Development of New Generation Cephalosporins to Combat Resistant Strains
    • Growing Demand for Broad-Spectrum Antibiotics in Clinical Settings
    • Global Increase in Bacterial Infections Driving Demand for Effective Treatments
    • Advances in Microbial Diagnostics Support Targeted Antibiotic Use
    • Market Challenges Posed by Generic Drug Competition
    • Research on Cephalosporin Use in Veterinary Medicine Expanding Market Dimensions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cephalosporin Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cephalosporin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Third Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fourth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fourth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Fourth Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Fifth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Fifth Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Fifth Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Skin Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Skin Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Skin Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Sexually Transmitted Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Sexually Transmitted Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Sexually Transmitted Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Urinary Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Respiratory Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Respiratory Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Respiratory Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Injection Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Injection Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Injection Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Cephalosporin Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Cephalosporin Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • INDIA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Cephalosporin Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Cephalosporin Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Cephalosporin Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030
  • AFRICA
    • Cephalosporin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Cephalosporin Drugs by Generation - First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Cephalosporin Drugs by Generation - Percentage Breakdown of Value Sales for First Generation, Second Generation, Third Generation, Fourth Generation and Fifth Generation for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Cephalosporin Drugs by Application - Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Cephalosporin Drugs by Application - Percentage Breakdown of Value Sales for Skin Infections Application, Sexually Transmitted Infections Application, Other Applications, Urinary Tract Infections Application and Respiratory Tract Infections Application for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Cephalosporin Drugs by Route Of Administration - Oral Route of Administration and Injection Route of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Cephalosporin Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration and Injection Route of Administration for the Years 2014, 2024 & 2030

IV. COMPETITION